RADIOGARDASE (PRUSSIAN BLUE)
LOE Approachingprussian blue insoluble capsules
NDAORALCAPSULEPriority Review
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
RADIOGARDASE (PRUSSIAN BLUE) (prussian blue insoluble capsules) is ion exchange activity [moa]. Approved for suspected internal contamination with radioactive cesium and/or radioactive, non-radioactive thallium to increase their rates of elimination. First approved in 2003.
Drug data last refreshed 17h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RADIOGARDASE is an oral decorporation agent containing insoluble prussian blue that works via ion exchange to bind radioactive cesium and non-radioactive thallium in the gastrointestinal tract, increasing their elimination rates. It is indicated for patients with suspected internal contamination from radioactive cesium and/or thallium exposure. This niche specialty product addresses a critical public health emergency use case with limited commercial volume.
LOE Approaching
As lifecycle approaches expiration, team size and investment in brand-building marketing are likely minimal; career growth opportunities center on regulatory, medical affairs, and emergency preparedness roles rather than commercial expansion.
Mechanism of Action
Ion Exchange Activity
Pharmacologic Class:
Decorporation Agent
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.